-
Something wrong with this record ?
Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus
Ivana Dostálová, Denisa Haluzíková, Martin Haluzík
Language English Country Czech Republic
NLK
Directory of Open Access Journals
from 1991
Free Medical Journals
from 1998
ProQuest Central
from 2005-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Nursing & Allied Health Database (ProQuest)
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- Diabetes Mellitus, Type 2 drug therapy metabolism MeSH
- Energy Metabolism drug effects MeSH
- Fibroblast Growth Factors metabolism therapeutic use drug effects MeSH
- Financing, Organized MeSH
- Hypoglycemic Agents adverse effects therapeutic use MeSH
- Anti-Obesity Agents adverse effects therapeutic use MeSH
- Humans MeSH
- Disease Models, Animal MeSH
- Obesity drug therapy metabolism MeSH
- Signal Transduction drug effects MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
Fibroblast growth factor 21 (FGF21) is a novel metabolic regulator produced primarily by the liver that exerts potent antidiabetic and lipid-lowering effects in animal models of obesity and type 2 diabetes mellitus. This hormone contributes to body weight regulation and is strongly involved in the response to nutritional deprivation and ketogenic state in mice. The principal sites of metabolic actions of FGF21 are adipose tissue, liver and pancreas. Experimental studies have shown marked improvements in diabetes compensation and dyslipidemia after FGF21 administration in diabetic mice and primates. Positive metabolic actions of FGF21 without the presence of apparent side effects make this factor a hot candidate to treat type 2 diabetes and accompanying metabolic diseases. The aim of this review is to summarize the current knowledge about the metabolic effects of FGF21 including some preliminary data on changes of its levels in humans with a special emphasis on its therapeutic potential in type 2 diabetes mellitus.
References provided by Crossref.org
Lit.: 43
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07528755
- 003
- CZ-PrNML
- 005
- 20111210145616.0
- 008
- 090915s2009 xr e eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.931610 $2 doi
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Dostálová, Ivana $7 xx0075775
- 245 10
- $a Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus / $c Ivana Dostálová, Denisa Haluzíková, Martin Haluzík
- 314 __
- $a Third Department of Medicine, First Faculty of Medicine, Charles University, Prague
- 504 __
- $a Lit.: 43
- 520 9_
- $a Fibroblast growth factor 21 (FGF21) is a novel metabolic regulator produced primarily by the liver that exerts potent antidiabetic and lipid-lowering effects in animal models of obesity and type 2 diabetes mellitus. This hormone contributes to body weight regulation and is strongly involved in the response to nutritional deprivation and ketogenic state in mice. The principal sites of metabolic actions of FGF21 are adipose tissue, liver and pancreas. Experimental studies have shown marked improvements in diabetes compensation and dyslipidemia after FGF21 administration in diabetic mice and primates. Positive metabolic actions of FGF21 without the presence of apparent side effects make this factor a hot candidate to treat type 2 diabetes and accompanying metabolic diseases. The aim of this review is to summarize the current knowledge about the metabolic effects of FGF21 including some preliminary data on changes of its levels in humans with a special emphasis on its therapeutic potential in type 2 diabetes mellitus.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a látky proti obezitě $x škodlivé účinky $x terapeutické užití $7 D019440
- 650 _2
- $a diabetes mellitus 2. typu $x farmakoterapie $x metabolismus $7 D003924
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a energetický metabolismus $x účinky léků $7 D004734
- 650 _2
- $a fibroblastové růstové faktory $x metabolismus $x terapeutické užití $x účinky léků $7 D005346
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypoglykemika $x škodlivé účinky $x terapeutické užití $7 D007004
- 650 _2
- $a obezita $x farmakoterapie $x metabolismus $7 D009765
- 650 _2
- $a signální transdukce $x účinky léků $7 D015398
- 700 1_
- $a Haluzíková, Denisa, $d 1970- $7 jo2003163140
- 700 1_
- $a Haluzík, Martin, $d 1970- $7 xx0000707
- 773 0_
- $w MED00003824 $t Physiological research $g Roč. 58, č. 1 (2009), s. 1-7 $x 0862-8408
- 856 41
- $u http://www.biomed.cas.cz/physiolres/pdf/58/58_1.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 4120 $c 266 $y 9
- 990 __
- $a 20090910142741 $b ABA008
- 991 __
- $a 20090915111128 $b ABA008
- 999 __
- $a ok $b bmc $g 679802 $s 539778
- BAS __
- $a 3
- BMC __
- $a 2009 $b 58 $c 1 $d 1-7 $i 0862-8408 $m Physiological research $x MED00003824
- LZP __
- $a 2009-31/mkme
